Electromed, Inc. ELMD

Company Overview

Electromed, Inc. (NYSE American: ELMD) is a U.S.-based medical device company focused on airway clearance therapy products for patients with compromised pulmonary function. The company operates within the respiratory care and durable medical equipment industries, primarily serving patients with chronic pulmonary conditions such as bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, neuromuscular disorders, and other conditions associated with impaired mucus clearance. Electromed’s primary revenue driver is its high frequency chest wall oscillation (HFCWO) therapy platform marketed under the SmartVest brand, which is prescribed by physicians and reimbursed through commercial insurers, Medicare, Medicaid, and other healthcare payors.

The company’s core positioning centers on non-invasive airway clearance therapy delivered through clinically supported and patient-focused respiratory care services. Electromed was founded in 1992 and evolved from a medical technology developer into a specialized respiratory therapy company focused on direct patient engagement, reimbursement support, and home-based pulmonary care solutions. Over time, the company expanded its market focus beyond cystic fibrosis into broader chronic respiratory disease populations, particularly non-cystic fibrosis bronchiectasis, which has become an increasingly important growth category in respiratory medicine.